A Phase 2 interventional study of zovaglutide Arm 1 and zovaglutide Arm 2 in Obesity, sponsored by Beijing QL Biopharmaceutical Co.,Ltd. Not yet recruiting at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Beijing QL Biopharmaceutical Co.,Ltd · Phase 2, Interventional, and Treatment
The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 210 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →Beijing QL Biopharmaceutical Co.,Ltd is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive zovaglutide dosing schedule 1 after randomization.
Drug: zovaglutide Arm 1
Participants will receive zovaglutide dosing schedule 2 after randomization.
Drug: zovaglutide Arm 2
Participants will receive semaglutide once weekly after randomization
Drug: semaglutide
Zovaglutide will be administered via subcutaneous (SC) injection.
Also known as: ZT002 Injection
Zovaglutide will be administered via subcutaneous (SC) injection.
Also known as: ZT002 Injection
Semaglutide will be administered via subcutaneous (SC) injection.
Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomization
Measure description:Definition of successful switch: Participants administered the target dose of assigned zovaglutide at both week28 and week32.
Time frame: from week 20 (randomization) to week 36
Proportion of participants achieving successful switch without severe gastrointestinal adverse event (GIAE)
Time frame: from week 20 (randomization) to week 36
Proportion of participants achieving successful switch without dose modification
Time frame: from week 20 (randomization) to week 36
Incidence of GIAE
Time frame: from week 20 (randomization) to week 40
Percentage of GIAE-free duration relative to total period after randomization
Time frame: from week 20 (randomization) to week 40
Changes in body weight from randomization
Time frame: from week 20 （ randomization) to week 36
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZT002
Beijing QL Biopharmaceutical Co.,Ltd →